Our Portfolio Planning & Risk Management Tutorials Part 1 & 2 are now available at HS Talks <read more here>                     We invite you to meet us at the BIO Int’l Convention at San Diego, June 19-22 <contact info>                     Our Portfolio Planning & Risk Management Tutorials Part 1 & 2 are now available at HS Talks <read more here>                     We invite you to meet us at the BIO Int’l Convention at San Diego, June 19-22 <contact info>                     Our Portfolio Planning & Risk Management Tutorials Part 1 & 2 are now available at HS Talks <read more here>                     We invite you to meet us at the BIO Int’l Convention at San Diego, June 19-22 <contact info>                     Our Portfolio Planning & Risk Management Tutorials Part 1 & 2 are now available at HS Talks <read more here>                     We invite you to meet us at the BIO Int’l Convention at San Diego, June 19-22 <contact info>                    
 
Home      About      Team      Clients      Publications      Downloads      News      Contact            

Testimonials
  Both, breadth and depth of Bioscience Valuation's economic assessments as well as the company's excellent knowledge of healthcare markets are invaluable assets for me in order to reach my goals.

Rick Jackson, Chairman and CEO
Jackson Healthcare

 

Core Services
  Financial Valuation
  Commercial Assessment &
Pharmacoeconomics

  R&D Risk Analysis &
Productivity Increase

  Portfolio Management
  Investment Decisions
  Partnering / Licensing
  Corporate Finance / M&A

Special Expertise
  Economic Modeling
of Healthcare Systems

  Assessing the Economics
of Personalized Medicine

Comprehensive Support
  Corporate Partnership Program

Products
  Market Model
  R&D Risk Model
  Valuation Model

Special Expertise - Economic Modeling of
Healthcare Systems


Healthcare Systems Modeling supports decision and policy makers in predicting the impact of new regulations or healthcare policies on their company's revenues. One example are new regulations to contain healthcare spending. Also, companies may design new products that are expected to have an impact on healthcare systems. Bioscience Valuation can assess the effects in a quantitative way. When modeling healthcare systems, Bioscience Valuation
  • collects all available information, either published and / or through interviews with relevant stakeholders,
  • a quantitative model is created and the available infomation is used to validate the model,
  • the impact of new regulations or new products is assessed and the results are analyzed,
  • a comprehensive report is generated that demonstrates the impact of the new policies or products,
  • Bioscience Valuation assists its clients in the communication of the healthcare modeling results.


Case:
A leading US-based healthcare service provider developed a new system that should produce considerable savings to payers. A Patients' Compensation System shall be introduced that could significantly reduce the practice of defensive medicine. Bioscience Valuation quantified the savings to Medicare, Medicaid and private insurance companies.

The new system is being implemented in Georgia and Florida. Bioscience Valuation's work is cited in the Wall Street Journal (WSJ March 20, 2013).